Premium
Improving monoclonal antibodies for cancer therapy
Author(s) -
Robinson M. K.,
Weiner L. M.,
Adams G. P.
Publication year - 2004
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.10345
Subject(s) - monoclonal antibody , antibody , cancer , cancer therapy , bispecific antibody , medicine , drug , targeted therapy , cancer treatment , cancer research , immunology , pharmacology
Monoclonal antibodies have emerged as a promising class of pharmaceuticals for the treatment of many human diseases, including cancer. Historically, an inability to target monoclonal antibodies to solid tumors in sufficient quantities and with high enough specificity has hampered the effectiveness of antibodies as therapeutics. This review focuses on recent efforts in the field of antibody‐engineering directed at improving both the targeting of antibody‐based therapeutics as well as enhancing the efficacy of those therapeutics once they have been targeted to tumor. Drug Dev. Res. 61:172–187, 2004. © 2004 Wiley‐Liss, Inc.